Elevai Labs reports Q4 results

seekingalpha03-30

Elevai Labs press release (NASDAQ:ELAB): Q4 total comprehensive loss was $708,508 Revenue increased to $698,591 for the three months ended December 31, 2023, compared to $138,898 for the three months...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2423497844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-30 00:51","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2423497844","market":"sg","top_or_hot":-1,"title":"Elevai Labs reports Q4 results","media":"seekingalpha","content":"<div>\n<p>Elevai Labs press release  (NASDAQ:ELAB): Q4 total comprehensive loss was $708,508\nRevenue increased to $698,591 for the three months ended December 31, 2023, compared to $138,898 for the three months...</p>\n\n<a href=\"https://seekingalpha.com/news/4085324-elevai-labs-reports-q4-results\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elevai Labs reports Q4 results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElevai Labs reports Q4 results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-30 00:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4085324-elevai-labs-reports-q4-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elevai Labs press release  (NASDAQ:ELAB): Q4 total comprehensive loss was $708,508\nRevenue increased to $698,591 for the three months ended December 31, 2023, compared to $138,898 for the three months...</p>\n\n<a href=\"https://seekingalpha.com/news/4085324-elevai-labs-reports-q4-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://seekingalpha.com/news/4085324-elevai-labs-reports-q4-results","article_id":"2423497844","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2423497844","pubTimestamp":1711731078,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Elevai Labs press release  : Q4 total comprehensive loss was $708,508. Revenueincreased to $698,591 for the three months ended December 31, 2023, compared to $138,898 for the three months ended December 31, 2022. More on Elevai Labs  ELEVAI LABS reports preliminary total net revenue for 2023 of over $1.635M ELAB, KIND and RLX among pre-market losers Financial information for Elevai Labs","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4526":"热门中概股","QID":"纳指两倍做空ETF","RLX":"雾芯科技","BK4075":"烟草","ELAB":"Elevai Labs, Inc.",".IXIC":"NASDAQ Composite","BK4183":"个人用品","QLD":"纳指两倍做多ETF","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","BK4563":"昨日强势股","TQQQ":"纳指三倍做多ETF","BK4551":"寇图资本持仓","SQQQ":"纳指三倍做空ETF"},"translate_title":"Elevai实验室报告第四季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAB":1,".IXIC":0.6,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"RLX":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Elevai Labs press release  (NASDAQ:ELAB): Q4 total comprehensive loss was $708,508\nRevenue increased to $698,591 for the three months ended December 31, 2023, compared to $138,898 for the three months ended December 31, 2022\n\n\nMore on Elevai Labs  ELEVAI LABS reports preliminary total net revenue for 2023 of over $1.635M ELAB, KIND and RLX among pre-market losers Financial information for Elevai Labs","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2423497844"}